Background

Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic disease that begins with simple fat accumulation and progresses to steatohepatitis (inflammation), fibrosis, and eventually cirrhosis and hepatocellular carcinoma (HCC). While affecting over 25% of the global population, the rate of progression and severity varies greatly among individuals. Even with similar alcohol intake or dietary habits, some remain at the simple steatosis stage, while others rapidly progress to malignant tumors.

In clinical settings, efforts have been made to find molecular genetic clues that explain these deviations. Past studies have also reported representative genes involved in hepatic fat accumulation, such as PNPLA3 and TM6SF2. However, it has been difficult to explain the complex phenotypic differences across entire populations with just a few of these variants. Previous cohort studies were limited to sample sizes of a few thousand and struggled to capture subtle genetic signals due to errors in measurement methods for quantifying liver fat, such as liver biopsy or ultrasound.

Intracellular triglyceride deposition in hepatocytes is the first trigger for disease progression. Therefore, a high-resolution genetic map capable of quantifying disease incidence by linking triglyceride levels—measured via precise large-scale imaging—with genomic information was urgently needed.

Key Findings

Researchers compared whole-genome sequences with abdominal MRI-based proton density fat fraction (PDFF) data from 71,488 UK Biobank participants using genome-wide association study (GWAS) techniques. The precise imaging measurements enabled quantification of intrahepatic triglyceride content without liver tissue damage.

The analysis identified 60 genomic loci independently associated with liver triglyceride accumulation. Notably, about 30 of these are new signals not previously captured in liver disease research. Based on these discovered variants, the researchers reconstructed key regulatory pathways involved in lipid metabolism, insulin signaling, and intracellular lipid droplet formation.

The research team constructed individual Polygenic Risk Scores (PGS) by converting the effect sizes of the 60 identified independent variants into weights. This score was not merely a predictor of simple liver fat volume. When linked with independent large-scale electronic health record (EHR) follow-up data, the top 10% high-risk PGS group showed a more than 3-fold increased risk of cirrhosis and a more than 2.5-fold increased risk of hepatocellular carcinoma compared to the bottom 10%. This provides numerical verification of the genetic trajectory in which fat accumulation in the liver parenchyma leads to long-term malignant diseases.

Significance and Outlook

This study expands liver metabolic disease research from a single-gene focus to a polygenic accumulation model. The 60 identified variants include protein groups involved not only in geological synthesis pathways but also in hepatic stellate cell activation and the creation of an inflammatory microenvironment. This provides a foundation for accelerating the discovery of new therapeutic targets. The development of RNA therapeutics or small molecule compounds that directly regulate the mechanisms of intrahepatic lipid accumulation, which were previously difficult to target, is expected to intensify.

Significant changes are also anticipated in screening systems for the early detection of high-risk groups with asymptomatic liver cancer progression. Even if standard liver function blood markers (AST/ALT) fall within the normal range, individuals with a high PGS may be prioritized for regular detailed ultrasound or MRI screenings.

However, the fact that this study's subjects are predominantly of European descent remains a challenge to address. Asian and African populations tend to exhibit different patterns of visceral fat accumulation relative to body mass index (BMI) and the incidence of liver fibrosis. Universal implementation of clinical practice guidelines will be realized only with subsequent validation in multi-ethnic cohorts and supporting functional genomic cellular experiments.